ロード中...
Tocilizumab in rheumatoid arthritis: efficacy, safety and its place in therapy
Tocilizumab is a humanized antihuman interleukin-6 (IL-6) receptor monoclonal antibody. It was developed in Japan as the first biological disease-modifying antirheumatic drug targeting IL-6 receptors. Many large-scale global studies have demonstrated its efficacy and safety, and in April 2008 it was...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3539265/ https://ncbi.nlm.nih.gov/pubmed/23342244 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040622312466908 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|